Search
Search Results
-
Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany
PurposeTo evaluate the cost-effectiveness of 177 Lu-PSMA-617 radioligand therapy (PRLT) in metastatic castration-resistant prostate cancer (mCRPC) in...
-
Guiding principles on the education and practice of theranostics
PurposeThe recent development and approval of new diagnostic imaging and therapy approaches in the field of theranostics have revolutionised nuclear...
-
Uptake of 68Ga-DOTATATE and 68Ga-DOTATOC in Primary Neuroendocrine Tumors, Metastases, and Normal Liver Tissue: Is There a Significant Difference?
Purpose: Intrapatient comparison of in vivo distribution of two Ga-68-labeled somatostatin (agonist) analogues with different in vitro affinities for...
-
Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles
PurposeCurrently, the most used peptide receptor radionuclide therapy (PRRT) regimen for neuroendocrine tumors comprises 4 treatment cycles, and...
-
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with...
-
Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics
In 1942, eighty years ago, Dr. Hertz first conducted radioiodine (RAI) diagnosis and therapy for thyroid disorders followed later by the successful...
-
The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study
IntroductionProstate-specific membrane antigen (PSMA)-based radioligand therapy (RLT) showed in a multicentre WARMTH (World Association of...
-
Neptune Examined: William Lassell, a Satellite, and Neptune’s “Ring”
One ‘discovery’ about Neptune proved to be nothing of the sort. William Lassell, one of the foremost British astronomers of the nineteenth century,...
-
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
IntroductionThe impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer...
-
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
PurposeTo assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with 177...
-
Radioimmunotherapy
Fighting the tumor cells comes natural to immune cells of our body; no wonder immunotherapy for cancer has become so successful. However, in some...
-
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
PurposePeptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment...
-
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can be identified by PSMA-ligand imaging, which has already...
-
Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer
BackgroundFor almost a decade, terbium radioisotopes have been explored for their potential theragnostic application in nuclear medicine: 152 Tb and 155...
-
Instant kit preparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [68Ga]Ga-DATA-TOC
PurposeThe widespread use of 68 Ga for positron emission tomography (PET) relies on the development of radiopharmaceutical precursors that can be...
-
Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake
PurposeProstate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging has impacted the management of patients with...
-
Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
Somatostatin receptors (SST), especially SST2A, are known for their overexpression in well-differentiated gastroenteropancreatic neuroendocrine...
-
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
BackgroundPeptide receptor radionuclide therapy (PRRT) utilizes somatostatin receptor (SSR) overexpression on neuroendocrine tumors (NET) to deliver...
